Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide added to standard induction chemotherapy for AML or RAEB
NL-OMON25046Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenalidomide in acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts (MDS-EB) (2 arms), sponsored by HOVON. Primary endpoints: Safety and tolerability in Part A, Complete remission rate in Part A and 3 more. Started Apr 2010; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome with excess blasts (MDS-EB)
Beyond the preview
Go deeper on NL-OMON25046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25046.